Skip to content
How It Works
Explore
Ask a Question Resources Pricing
Who It's For
Patients
Decode results, prep for appointments, weigh options.
Caregivers & advocates
Carry the research load for someone you love.
Providers & clinicians
Resources for patients in your practice.
Log In Ask a Question
PubMed This is a summary of 20 peer-reviewed journal articles Updated
Urology · Benign Prostatic Hyperplasia

Medication Options for an Enlarged Prostate

At a Glance

BPH medicines work in different ways: alpha-blockers relax the prostate for relief within days, while finasteride or dutasteride shrink a larger prostate over months. Combination therapy may reduce future urinary blockage, but side effects and drug interactions require clinician guidance.

When watchful waiting is no longer enough to manage your symptoms, medication is typically the next step. Because Benign Prostatic Hyperplasia (BPH) involves both physical growth and muscle tension, doctors use several different classes of drugs to address these issues. The goal is to improve your quality of life. Some medications provide rapid symptom relief, while others physically shrink the prostate reducing the long-term risk of serious complications like being unable to urinate (acute retention) [1][2].

Rapid Relief: Alpha-Blockers

Alpha-blockers are the most common first-line treatment for BPH. They work by relaxing the smooth muscle in the prostate and the neck of the bladder, making it easier for urine to flow [1][3]. These medications, which include tamsulosin, alfuzosin, and silodosin, usually provide symptom relief within a few days [4]. Alpha-blockers generally improve symptoms and flow relatively quickly, but do not shrink the prostate or prevent long-term disease progression.

  • Efficacy: Most alpha-blockers provide similar levels of symptom improvement [4][5].
  • Common Side Effects: Because these drugs relax blood vessels, they can cause dizziness, lightheadedness, or a drop in blood pressure when you stand up (orthostatic hypotension) [6][7]. Dizziness and visual impairment from blood pressure drops can contribute to falls, especially in older adults, so rise slowly from a sitting position.
  • Sexual Side Effects: Some men experience “retrograde ejaculation” (where semen enters the bladder instead of exiting the penis). This is most common with silodosin [8][5].

Shrinking the Prostate: 5-Alpha-Reductase Inhibitors (5-ARIs)

If your prostate is larger (typically over 30 cc or 30 mL), your doctor may prescribe a 5-ARI such as finasteride or dutasteride [1][9]. These drugs block the production of dihydrotestosterone (DHT), the hormone that fuels prostate growth [10].

  • Efficacy: These medications physically shrink the prostate by about 20% to 25% over time [9]. This reduces your long-term risk of needing surgery or experiencing an emergency blockage [9][11].
  • Timing: Unlike alpha-blockers, 5-ARIs work slowly. You may not notice a significant change in your symptoms for 6 to 12 months [9].
  • Key Considerations: 5-ARIs can lower your libido (sex drive) or cause erectile dysfunction in a small percentage of men [9][12]. They also lower your PSA levels by about 50%, which your doctor must account for when screening for prostate cancer [13][14]. Your doctor will usually establish a new PSA baseline after the drug takes effect, and any unexpected PSA rise should be evaluated. They can also reduce ejaculate volume, and rarely cause breast tenderness or mood effects.

Combination Therapy: A Stronger Approach

For men with larger prostates who have a high risk of their condition getting worse, doctors often recommend taking both an alpha-blocker and a 5-ARI together [1][2].

  • The Benefit: This combination provides the “best of both worlds”—the alpha-blocker gives rapid symptom relief, while the 5-ARI works in the background to shrink the prostate and prevent future complications [11][2].
  • The Result: Studies show that combination therapy reduces the risk of disease progression (such as surgery or emergency room visits) more effectively than taking either drug alone [11][15].

Other Options: Tadalafil and Bladder-Focused Meds

If standard BPH drugs aren’t the right fit, or if you have specific symptoms, other medications can help:

  • Tadalafil: Originally for erectile dysfunction, this medication is also approved for BPH. It improves BPH symptoms and erectile function at a low daily dose, though objective improvement in urinary flow is not guaranteed [1][16]. Safety warning: Tadalafil must not be used with nitrates (like nitroglycerin) or riociguat, and requires a clinician review if you take alpha-blockers, antihypertensives, or have certain heart conditions due to the risk of dangerous low blood pressure.
  • Antimuscarinics and Beta-3 Agonists: If your main problem is urgency or frequent trips to the bathroom (storage symptoms) that don’t improve with an alpha-blocker, your doctor might add a drug like solifenacin or mirabegron [17][2]. These medications focus on relaxing the bladder muscle itself [18][19]. However, they are used cautiously if you have trouble emptying your bladder completely, as they can sometimes increase the amount of urine left behind [18][20]. Antimuscarinics can cause dry mouth, constipation, blurred vision, and sometimes cognitive effects. Mirabegron can raise blood pressure and has specific drug interactions, so your clinician will follow your symptoms and emptying.

Common questions in this guide

Which medicines provide the fastest relief for BPH symptoms?
Alpha-blockers such as tamsulosin, alfuzosin, and silodosin usually relax the prostate and bladder outlet enough to improve symptoms within a few days. They can improve urine flow, but they do not shrink the prostate or prevent long-term enlargement.
When are finasteride or dutasteride used for an enlarged prostate?
Finasteride and dutasteride are often considered when the prostate is larger, typically over 30 cc or 30 mL. They can shrink the prostate over time and lower the risk of urinary blockage or surgery, but noticeable symptom improvement may take 6 to 12 months.
How do BPH medicines affect PSA testing?
Finasteride and dutasteride can lower PSA levels by about 50 percent. The clinician monitoring you will account for this change, establish a new PSA baseline after treatment takes effect, and evaluate an unexpected rise.
Can I take tadalafil for BPH with my heart or blood pressure medicines?
Tadalafil must not be taken with nitrate medicines such as nitroglycerin or with riociguat because the combination can cause a dangerous drop in blood pressure. A clinician should also review its use with alpha-blockers, blood pressure medicines, and certain heart conditions.
Can bladder medicines be added if BPH causes urgency and frequent urination?
Medicines such as solifenacin or mirabegron may help urgency and frequent urination when these symptoms persist. They require caution if you do not empty your bladder completely, because some can increase urine left in the bladder; mirabegron can also raise blood pressure.
Why might a doctor prescribe two BPH medicines together?
An alpha-blocker can provide relatively rapid symptom relief, while a 5-alpha-reductase inhibitor gradually shrinks the prostate and lowers the risk of future complications. This combination is often considered for men with larger prostates and a higher risk of progression.

Questions to Ask Your Doctor

Curated prompts to bring to your next appointment.

  1. 1.Given my prostate size and PSA levels, am I at high risk for disease progression, and should we consider combination therapy?
  2. 2.Now that I am starting a 5-alpha-reductase inhibitor like finasteride, when should we re-check my PSA to establish a new baseline?
  3. 3.Is a 'uroselective' alpha-blocker like silodosin better for me, or does it carry too high a risk of ejaculatory changes?
  4. 4.Are there any risks combining tadalafil with my current blood pressure medications, nitrates, or any heart conditions I have?
  5. 5.If my urgency symptoms don't improve, is it safe to add an antimuscarinic considering my post-void residual volume?

Questions For You

Tap a prompt to share your answer — we'll use it plus this page's context to start a tailored conversation.

References

References (20)
  1. 1

    How Would You Manage This Patient With Benign Prostatic Hyperplasia? : Grand Rounds Discussion From Beth Israel Deaconess Medical Center.

    Smetana GW, Smith CC, Singla A, Libman H

    Annals of internal medicine 2023; (176(4)):545-555 doi:10.7326/M23-0113.

    PMID: 37037036
  2. 2

    [Pharmacological treatment of benign prostatic hyperplasia].

    Oelke M, Martinelli E

    Der Urologe. Ausg. A 2016; (55(1)):81-94; quiz 95-6 doi:10.1007/s00120-015-0011-3.

    PMID: 26676726
  3. 3

    Pathophysiological mechanisms of benign prostatic obstruction in men with small prostate volume and the emerging role of ultra-minimally invasive prostatic urethral dilation: a narrative review.

    Shen K, Zhang D, Yu L

    Frontiers in molecular biosciences 2026; (13()):1886121 doi:10.3389/fmolb.2026.1886121.

    PMID: 42620960
  4. 4

    A randomized, comparative, open-label study of efficacy and tolerability of alfuzosin, tamsulosin and silodosin in benign prostatic hyperplasia.

    Manjunatha R, Pundarikaksha HP, Madhusudhana HR, et al.

    Indian journal of pharmacology 2016; (48(2)):134-40 doi:10.4103/0253-7613.178825.

    PMID: 27127315
  5. 5

    Silodosin for the treatment of lower urinary tract symptoms in men with benign prostatic hyperplasia.

    Jung JH, Kim J, MacDonald R, et al.

    The Cochrane database of systematic reviews 2017; (11()):CD012615 doi:10.1002/14651858.CD012615.pub2.

    PMID: 29161773
  6. 6

    Efficacy and safety of adrenergic alpha-1 receptor antagonists in older adults: a systematic review and meta-analysis supporting the development of recommendations to reduce potentially inappropriate prescribing.

    Mansbart F, Kienberger G, Sönnichsen A, Mann E

    BMC geriatrics 2022; (22(1)):771 doi:10.1186/s12877-022-03415-7.

    PMID: 36171560
  7. 7

    Management of use of urinary antimuscarinics and alpha blockers for benign prostatic hyperplasia in older adults at risk of falls: a clinical review.

    İlhan B, Erdoğan T, Topinková E, et al.

    European geriatric medicine 2023; (14(4)):733-746 doi:10.1007/s41999-023-00798-7.

    PMID: 37245173
  8. 8

    Effect of alpha-adrenoceptor antagonists on sexual function. A systematic review and meta-analysis.

    Bapir R, Bhatti KH, Eliwa A, et al.

    Archivio italiano di urologia, andrologia : organo ufficiale [di] Societa italiana di ecografia urologica e nefrologica 2022; (94(2)):252-263 doi:10.4081/aiua.2022.2.252.

    PMID: 35775356
  9. 9

    The use of 5-alpha reductase inhibitors in the treatment of benign prostatic hyperplasia.

    Kim EH, Brockman JA, Andriole GL

    Asian journal of urology 2018; (5(1)):28-32 doi:10.1016/j.ajur.2017.11.005.

    PMID: 29379733
  10. 10

    Mechanism of Androgen-Independent Stromal Proliferation in Benign Prostatic Hyperplasia.

    Hata J, Harigane Y, Matsuoka K, et al.

    International journal of molecular sciences 2023; (24(14)) doi:10.3390/ijms241411634.

    PMID: 37511400
  11. 11

    Lower Urinary Tract Symptoms in Men: A Review.

    Wei JT, Dauw CA, Brodsky CN

    JAMA 2025; (334(9)):809-821 doi:10.1001/jama.2025.7045.

    PMID: 40658396
  12. 12

    Pharmacological treatment of lower urinary tract symptoms in benign prostatic hyperplasia: consequences on sexual function and possible endocrine effects.

    La Vignera S, Aversa A, Cannarella R, et al.

    Expert opinion on pharmacotherapy 2021; (22(2)):179-189 doi:10.1080/14656566.2020.1817382.

    PMID: 32902360
  13. 13

    Glucocorticoids are induced while dihydrotestosterone levels are suppressed in 5-alpha reductase inhibitor treated human benign prostate hyperplasia patients.

    Jin R, Forbes C, Miller NL, et al.

    The Prostate 2022; (82(14)):1378-1388 doi:10.1002/pros.24410.

    PMID: 35821619
  14. 14

    Genome-wide associations for benign prostatic hyperplasia reveal a genetic correlation with serum levels of PSA.

    Gudmundsson J, Sigurdsson JK, Stefansdottir L, et al.

    Nature communications 2018; (9(1)):4568 doi:10.1038/s41467-018-06920-9.

    PMID: 30410027
  15. 15

    Efficacy and safety of a fixed-dose combination of dutasteride and tamsulosin treatment (Duodart(®) ) compared with watchful waiting with initiation of tamsulosin therapy if symptoms do not improve, both provided with lifestyle advice, in the management of treatment-naïve men with moderately symptomatic benign prostatic hyperplasia: 2-year CONDUCT study results.

    Roehrborn CG, Oyarzabal Perez I, Roos EP, et al.

    BJU international 2015; (116(3)):450-9 doi:10.1111/bju.13033.

    PMID: 25565364
  16. 16

    A Review of Combined Phosphodiesterase-5-Inhibitors and α-Blockers versus Phosphodiesterase-5-Inhibitors Alone for Lower Urinary Tract Symptoms due to Benign Prostatic Hyperplasia.

    Jackson EM, Khooblall P, Lundy SD, Bajic P

    Arab journal of urology 2024; (22(1)):13-23 doi:10.1080/2090598X.2023.2220627.

    PMID: 38205391
  17. 17

    Non-interventional and medical management of lower urinary tract symptoms related to benign prostatic hyperplasia in men: Guidelines of the French LUTS Committee (CTMH).

    Anract J, Klein C, Sarrazin C, et al.

    The French journal of urology 2025; (35(11)):102952 doi:10.1016/j.fjurol.2025.102952.

    PMID: 41271371
  18. 18

    Tamsulosin combined with solifenacin versus tamsulosin monotherapy for male lower urinary tract symptoms: a meta-analysis.

    Gong M, Dong W, Huang G, et al.

    Current medical research and opinion 2015; (31(9)):1781-92 doi:10.1185/03007995.2015.1074067.

    PMID: 26211817
  19. 19

    Medical Advancements in Benign Prostatic Hyperplasia Treatments.

    Ganesan V, Agarwal D

    Current urology reports 2024; (25(5)):93-98 doi:10.1007/s11934-024-01199-4.

    PMID: 38448685
  20. 20

    Intravesical prostatic protrusion does not compromise the therapeutic effects of Mirabegron in male patients with overactive bladder.

    Shen YC, Wang HJ, Lee WC, et al.

    International journal of clinical practice 2020; (74(9)):e13537 doi:10.1111/ijcp.13537.

    PMID: 32438481

This page explains medication choices for benign prostatic hyperplasia for educational purposes and does not replace medical advice. A urologist or prescribing clinician should review your symptoms, other medicines, prostate size, PSA results, and health history.

Get notified when new evidence is published on prostatic adenoma.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.